Search company, investor...
Arvelle Therapeutics company logo

Arvelle Therapeutics

arvelletx.com

Founded Year

2019

Stage

Acquired | Acquired

Total Raised

$207.8M

Valuation

$0000 

About Arvelle Therapeutics

Arvelle Therapeutics seeks to bring CNS products to patients suffering from neurological conditions. On January 4th, 2021, Arvelle Therapeutics was acquired by Angelini Pharma.

Headquarters Location

Zählerweg 6

Zug, 6300,

Switzerland

888-317-1041

Missing: Arvelle Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Arvelle Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Arvelle Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arvelle Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Arvelle Therapeutics News

NICE recommends Angelini’s Ontozry for the treatment of focal-onset seizures

Nov 15, 2021

Switzerland-based Arvelle Therapeutics, which was acquired by Italy’s Angelini earlier this year, today… To continue reading The Pharma Letter please login ,   subscribe  or  claim a 7 day free trial subscription  and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.

Arvelle Therapeutics Frequently Asked Questions (FAQ)

  • When was Arvelle Therapeutics founded?

    Arvelle Therapeutics was founded in 2019.

  • Where is Arvelle Therapeutics's headquarters?

    Arvelle Therapeutics's headquarters is located at Zählerweg 6, Zug.

  • What is Arvelle Therapeutics's latest funding round?

    Arvelle Therapeutics's latest funding round is Acquired.

  • How much did Arvelle Therapeutics raise?

    Arvelle Therapeutics raised a total of $207.8M.

  • Who are the investors of Arvelle Therapeutics?

    Investors of Arvelle Therapeutics include Angelini Pharma, EQT Life Sciences, Andera Partners, QHP Capital, H.I.G. BioHealth Partners and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.